GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (NAS:ORKA) » Definitions » Quick Ratio

ORKA (Oruka Therapeutics) Quick Ratio : 28.89 (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Oruka Therapeutics's quick ratio for the quarter that ended in Dec. 2024 was 28.89.

Oruka Therapeutics has a quick ratio of 28.89. It generally indicates good short-term financial strength.

The historical rank and industry rank for Oruka Therapeutics's Quick Ratio or its related term are showing as below:

ORKA's Quick Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.38
* Ranked among companies with meaningful Quick Ratio only.

Oruka Therapeutics Quick Ratio Historical Data

The historical data trend for Oruka Therapeutics's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics Quick Ratio Chart

Oruka Therapeutics Annual Data
Trend Dec24
Quick Ratio
28.89

Oruka Therapeutics Semi-Annual Data
Dec24
Quick Ratio 28.89

Competitive Comparison of Oruka Therapeutics's Quick Ratio

For the Biotechnology subindustry, Oruka Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oruka Therapeutics's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oruka Therapeutics's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Oruka Therapeutics's Quick Ratio falls into.


;
;

Oruka Therapeutics Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Oruka Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Quick Ratio (A: Dec. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(376.869-0)/13.043
=28.89

Oruka Therapeutics's Quick Ratio for the quarter that ended in Dec. 2024 is calculated as

Quick Ratio (Q: Dec. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(376.869-0)/13.043
=28.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oruka Therapeutics  (NAS:ORKA) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Oruka Therapeutics Quick Ratio Related Terms

Thank you for viewing the detailed overview of Oruka Therapeutics's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Oruka Therapeutics Business Description

Traded in Other Exchanges
Address
855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.